Epizyme Inc (EPZM) Receives $19.00 Average Target Price from Analysts

Shares of Epizyme Inc (NASDAQ:EPZM) have been assigned a consensus rating of “Buy” from the thirteen analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.00.

EPZM has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating and set a $18.00 price objective on shares of Epizyme in a research report on Tuesday, February 26th. BidaskClub raised shares of Epizyme from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Oppenheimer decreased their price objective on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, February 27th. Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a research report on Wednesday, February 27th. Finally, ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th.

A number of large investors have recently made changes to their positions in the stock. Primecap Management Co. CA raised its stake in Epizyme by 7.3% during the 1st quarter. Primecap Management Co. CA now owns 10,253,801 shares of the biopharmaceutical company’s stock worth $127,045,000 after acquiring an additional 697,274 shares in the last quarter. Redmile Group LLC raised its stake in Epizyme by 15.9% during the 1st quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s stock worth $95,329,000 after acquiring an additional 1,056,742 shares in the last quarter. BlackRock Inc. raised its stake in Epizyme by 19.0% during the 4th quarter. BlackRock Inc. now owns 5,193,287 shares of the biopharmaceutical company’s stock worth $31,990,000 after acquiring an additional 830,815 shares in the last quarter. Vanguard Group Inc. raised its stake in Epizyme by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,570,139 shares of the biopharmaceutical company’s stock worth $48,443,000 after acquiring an additional 84,726 shares in the last quarter. Finally, FMR LLC raised its stake in Epizyme by 0.3% during the 1st quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock worth $43,169,000 after acquiring an additional 11,759 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Epizyme stock opened at $13.49 on Tuesday. Epizyme has a 12-month low of $5.14 and a 12-month high of $17.00. The company has a current ratio of 12.55, a quick ratio of 12.55 and a debt-to-equity ratio of 0.03.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. The firm had revenue of $7.89 million for the quarter, compared to analysts’ expectations of $1.13 million. As a group, analysts forecast that Epizyme will post -2 EPS for the current fiscal year.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

See Also: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.